Karen Knudsen shared a post by American Cancer Society on LinkedIn, adding:

“Our work with Genentech reflects the depth and breadth of our commitments to improving the lives of cancer patients and their families across the continuum of care. The strength of our partnership derives from aligned organizational priorities and proven success in addressing emergent needs and barriers to care, as we work to end cancer as we know it, for everyone.”

Quoting American Cancer Society’s post:

“We’re thrilled to mark another year of success and progress tackling health disparities alongside our valued partner, Genentech. In 2023, nearly 375,000 cancer screenings were completed through community-based screening interventions. Building on these achievements, we’re excited to announce that the work continues in 2024.

We are focused on piloting health-related social needs screening and referral projects in three key regions: Georgia, Ohio, and Oregon.

These programs aim to accelerate community-based interventions with health system partners that directly improve health equity and cancer outcomes. We look forward to sharing more about our work together throughout this year.”

View additional information.
Source: Karen Knudsen/LinkedIn and American Cancer Society/LinkedIn

Karen Knudsen is the CEO of the American Cancer Society (ACS) and its advocacy affiliate, the American Cancer Society Cancer Action Network (ACS CAN). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health.

She also served as president for the Association of American Cancer Institutes (AACI), representing the 102 leading cancer centers in North America, and on the board of directors of the American Association for Cancer Research (AACR). Dr. Knudsen currently holds leadership roles with some of the most important cancer entities in the United States.

She serves on the board of advisors for the National Cancer Institute and on 12 external advisory boards for NCI-designated cancer centers. She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.